Aelis Farma is developing AEF0117, a selective CB1 receptor negative allosteric modulator, representing a novel pharmacological approach to cannabis use disorder. Their financial stability and pipeline progression directly impacts when clinicians might have access to the first FDA-approved medication specifically targeting problematic cannabis use.
Aelis Farma continues development of AEF0117, which works by modulating CB1 receptors without blocking them completely, potentially reducing cannabis cravings and use without the adverse effects seen with full CB1 antagonists like rimonabant. The company’s 2026 outlook suggests continued clinical trial progression for cannabis use disorder, though specific efficacy data and trial timelines require monitoring. This represents part of a broader pharmaceutical interest in developing targeted treatments for cannabis use disorder as legalization expands.
“We desperately need evidence-based treatments for cannabis use disorder, and AEF0117’s mechanism is genuinely interesting from a receptor pharmacology standpoint. However, until we see robust Phase II data, this remains a promising but unproven approach.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is Cannabis Use Disorder?
Cannabis Use Disorder is a medical condition characterized by problematic cannabis use leading to clinically significant impairment or distress. It involves tolerance, withdrawal symptoms, and inability to control or reduce cannabis consumption despite negative consequences.
What is the CB1 receptor and why is it important?
The CB1 receptor is the primary cannabinoid receptor in the brain that mediates the psychoactive effects of THC. It plays a crucial role in cannabis addiction and is a key target for developing treatments for Cannabis Use Disorder.
How is addiction medicine addressing cannabis dependency?
Addiction medicine specialists are developing comprehensive treatment approaches that combine behavioral therapies with potential pharmacological interventions. Current research focuses on medications that can help reduce cannabis cravings and withdrawal symptoms.
What pharmaceutical developments are being pursued for cannabis addiction?
Pharmaceutical companies are investigating CB1 receptor antagonists and other compounds that could help treat Cannabis Use Disorder. These medications aim to reduce the rewarding effects of cannabis and help patients maintain abstinence.
Why is this considered notable clinical interest?
Cannabis Use Disorder affects millions globally, yet effective pharmacological treatments remain limited. The emergence of new research and potential therapeutic targets represents significant progress in addressing this growing public health concern.
